fluorouracil, 5-FU
information and resources from the National Cancer Institute
Adrucil
prolong survival in combination with leucovorin
ICN Puerto Rico Apr 25 1962
|
|
|
|
news articles
Pro-Pharmaceuticals cancer trial on track 01 Apr 2006
Pharmaceutical Business Review ...patients with colon cancer, which has spread despite treatment with approved therapies, are receiving Davanat plus 5-fluorouracil (5-FU) in monthly cycles for ...
Pro-Pharmaceuticals Completes Patient Enrollment in Stage 1 of ... Mar 30, 2006
Genetic Engineering News, ...study, patients with colon cancer, which has spread despite treatment with approved therapies, are receiving DAVANAT(R) plus 5-Fluorouracil (5-FU) in monthly ...
Pro-Pharma Completes Patient Enrollment In Stage 1 Of Phase II ... Mar 30, 2006
Trading Markets, In this Phase II study, patients with colon cancer are receiving DAVANAT plus 5-Fluorouracil (5-FU | charts | news | Powerrating) in monthly cycles for at ...
Pro-Pharmaceuticals' Abstract Accepted for Publication in ASCO ... Mar 17, 2006
International News Service, The study uses radio-labeled, 5-Fluorouracil (5-FU) to study the bio-distribution in the bloodstream, tumor and other organs alone and when co-administered ...
Pro-Pharmaceuticals To Present Details Of Phase I Trial Of DAVANAT ... Mar 17, 2006
Trading Markets, ...solid tumors that were not open to surgery, radiation, or chemotherapy and also, were not responding to radio-labeled, 5-Fluorouracil (5-FU | charts | news ...
Taxotere® Approved for Advanced Gastric Cancer Mar 24, 2006
Cancer Consultants (press release), There are several standard chemotherapy regimens for metastatic gastric cancer, all of which include the agent 5-fluorouracil (5-FU). ...
Spectrum Pharmaceuticals to Acquire NDA for an Oncology Drug and ... Mar 20, 2006
PR Newswire (press release), ...acquired is levofolinic acid (LFA), the pure active isomer of calcium leucovorin, a component of "standard of care" 5-fluorouracil (5-FU) containing regimens ...
Spectrum to acquire Targent's cancer assets Mar 21, 2006
Pharmaceutical Business Review ...acid (LFA), the pure active isomer of calcium leucovorin, a component of cancer standard of care treatment 5-fluorouracil (5-FU) containing regimens for the ...
Pro-Pharmaceuticals to Present Abstract & Poster at Mass ... Mar 2, 2006
Genetic Engineering News, ..."The data indicates DAVANAT(R) exhibits broad spectrum enhancement of anti-tumor drugs, including 5-Fluorouracil (5-FU), Irinotecan, and AVASTIN(R) in human ...
Tomudex® Plus Eloxatin® Effective in Gemzar®-Resistant ... Mar 24, 2006
Cancer Consultants (press release), ...to 18%. Active drugs for pancreatic cancer also include the anti-folate drugs, such as 5-fluorouracil (5-FU). Alimta® (pemetrexed ...
Former Texas Gov. Ann Richards has esophagus cancer Mar 9, 2006
Food Consumer, ...depends on the tumor type, but tends to be cisplatin-based (or carboplatin or oxaliplatin) every three weeks with fluorouracil (5-FU) either continuously or ...
Addition of Erbitux® to Chemotherapy Promising as Initial ... Mar 7, 2006
Cancer Consultants (press release), ...of Oncology, the addition of Erbitux® (cetuximab) to the chemotherapy combination consisting of Camptosar® (irinotecan), 5-fluorouracil (5-FU), and folinic ...
Treatment Standard for Elderly With Colon Cancer Mar 9, 2006
eMaxHealth.com, ...against colorectal cancer of the chemotherapy regimen known as FOLFOX4, a combination of the standard anticancer drugs 5-fluorouracil (5-FU), leucovorin and ...
Adherex Receives FDA Orphan Drug Designation for Eniluracil in ... 21 Dec 2005
CCNMatthews (press release), ...of hepatocellular cancer. The fluoropyrimidines include 5-fluorouracil (5-FU) and other 5-FU prodrugs. Adherex's global development ...
International Approvals: Metvix, Atec System, CardioWest ... 21 Dec 2005
Medscape (subscription) ...treated with MAL-PDT achieved complete response at 1 year, compared with 86% and 83% of those treated with cryotherapy and 5-fluorouracil (5-FU), respectively. ...
Genentech Submits Supplemental Biologics License Application for ... Dec 19, 2005
Yahoo! News (press release) Application (sBLA) with the US Food and Drug Administration (FDA) for Avastin® (bevacizumab) in combination with 5-fluorouracil (5-FU)-based chemotherapy for ...
Plenary Session Snapshot Dec 19, 2005
Medscape (subscription) ...rectum, stage T3-4, Nx, to radiotherapy alone (45 Gy in 25 fractions) or same RT with concurrent chemotherapy consisting of bolus 5-fluorouracil (5-FU) 350 mg ...
Addition of Taxol® to Chemotherapy Combination Improves Survival ... Nov 29, 2005
Cancer Consultants (press release), Journal of Clinical Oncology, the addition of the chemotherapy agent Taxol® (paclitaxel) to Platinol® (cisplatin) and 5-fluorouracil (5-FU) improves outcomes ...
ADVENTRX Announces Positive FDA Pre-IND Meeting Outcome Dec 7, 2005
Biotech Intelligence (press release), ...resistance. The Company's lead compound, CoFactor(TM), is a biomodulator of 5-fluorouracil (5-FU), a widely used cancer chemotherapy. ...
Two-Thirds of Patients with Stage III Colon Cancer Receive ... Dec 7, 2005
Cancer Consultants (press release), ...treatment). A chemotherapy regimen typically consists of the agent 5-fluorouracil (5-FU) alone or in combination with other agents. ...
ADVENTRX to Present at Informed Investors Bay Area Biotechnology ... Dec 1, 2005
PR Newswire (press release), The Company's lead compound, CoFactor(TM), is a biomodulator of 5-fluorouracil (5-FU), a widely used cancer chemotherapy agent. ...
Molecular Advances Driving New Approaches in Colorectal Cancer ... Nov 18, 2005
DG News One of the hottest developments involves cetuximab in metastatic CRC, as either a single agent for patients refractory to 5-fluorouracil (5-FU)/oxaliplatin or ...
|
|
